Azathioprine

Azathioprine
Ayacop · Public domain · source
Name	Azathioprine
Tradename	Imuran, Azasan
Legal status	Prescription only
Routes of administration	Oral, intravenous
Class	Immunosuppressant, antimetabolite
Metabolism	Hepatic (including xanthine oxidase)
Elimination half-life	~5 hours (active metabolites longer)
Excretion	Renal

Azathioprine is an immunosuppressive antimetabolite used to prevent organ transplant rejection and to treat a range of autoimmune disorders. Originally developed in the mid-20th century, it remains on many essential medicine lists and is widely used in transplant centers and rheumatology, dermatology, and gastroenterology clinics. Clinical practice guidelines from transplant societies and specialty organizations continue to include azathioprine as an option for steroid-sparing therapy and long-term maintenance.

Medical uses

Azathioprine is used to prevent rejection after solid organ transplantation and graft-versus-host disease management in hematopoietic stem cell transplants, appearing in protocols from institutions such as Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic, Massachusetts General Hospital, and Karolinska Institutet. In rheumatology it treats autoimmune diseases referenced by organizations like the American College of Rheumatology, European League Against Rheumatism, British Society for Rheumatology, and specialty centers including Mount Sinai Hospital; conditions include systemic lupus erythematosus, vasculitis, and rheumatoid arthritis when disease-modifying agents are indicated. Gastroenterology guidelines from groups such as the American Gastroenterological Association, European Crohn's and Colitis Organisation, National Institute for Health and Care Excellence, and major hospitals endorse azathioprine for maintenance of remission in inflammatory bowel diseases including Crohn's disease and ulcerative colitis. Dermatology uses are described in literature from the American Academy of Dermatology and clinics such as Mayo Clinic Florida for pemphigus vulgaris and other autoimmune blistering diseases. Neurology case series from centers like Hospital for Special Surgery and academic departments have reported off-label use in neuromyelitis optica spectrum disorders and autoimmune encephalitis.

Mechanism of action

Azathioprine is a prodrug metabolized to 6-mercaptopurine and subsequently to active thioguanine nucleotides, with biochemical effects characterized in studies from institutions such as Harvard Medical School and Oxford University. The active metabolites inhibit purine synthesis pathways and become incorporated into DNA and RNA, disrupting lymphocyte proliferation as detailed in biochemical reviews authored by researchers affiliated with National Institutes of Health, University College London, Yale School of Medicine, and Stanford University School of Medicine. Enzymes including xanthine oxidase, thiopurine methyltransferase, and hypoxanthine-guanine phosphoribosyltransferase—investigated by teams at University of Cambridge, Karolinska Institutet, and University of Tokyo—modulate conversion and toxicity profiles. Pharmacogenetic variability, especially TPMT polymorphisms identified in genetic studies from University of Washington, Broad Institute, and Wellcome Sanger Institute, alters risks of myelosuppression and guides dose adjustment per guidelines from Clinical Pharmacogenetics Implementation Consortium and national regulators like the Food and Drug Administration.

Pharmacokinetics

Oral azathioprine is absorbed and converted to 6-mercaptopurine in vivo, with hepatic and extrahepatic metabolism characterized in pharmacology reports from Pfizer and academic pharmacokinetic groups at University of Chicago and University of California, San Francisco. Xanthine oxidase activity, studied by researchers at Cornell University and Imperial College London, substantially affects bioavailability and clearance; coadministration with xanthine oxidase inhibitors modifies systemic exposure, a phenomenon noted in clinical alerts issued by European Medicines Agency and the Food and Drug Administration. Renal excretion of metabolites and intracellular retention of thioguanine nucleotides determine duration of immunosuppressive effect; monitoring practices are described in transplant center protocols at UCLA Medical Center and Johns Hopkins Hospital.

Adverse effects

Bone marrow suppression leading to leukopenia, anemia, and thrombocytopenia is a major toxicity highlighted in safety communications from FDA and clinical reviews in journals affiliated with American Society of Hematology, European Society for Medical Oncology, and American Society of Transplantation. Hepatotoxicity, pancreatitis, and gastrointestinal intolerance have been reported in case series from Mayo Clinic, Mount Sinai Hospital, and European tertiary centers. Long-term use is associated with increased risk of malignancies, particularly non-melanoma skin cancers and lymphoproliferative disorders, with epidemiological data from cohorts at Karolinska Institutet, University of Oxford, University of Paris, and national registries in Sweden and Denmark. Hypersensitivity reactions described in reports from Johns Hopkins Hospital and Royal Free Hospital can mimic sepsis or vasculitis. Pregnancy exposure studies coordinated by groups such as European Network of Teratology Information Services and Centers for Disease Control and Prevention inform risk counseling.

Contraindications and precautions

Azathioprine is contraindicated or used with extreme caution in patients with known hypersensitivity reactions documented in hospital adverse event databases at Guy's and St Thomas' NHS Foundation Trust and other centers. Severe leukopenia, active severe infections tracked by World Health Organization surveillance, and pregnancy considerations per guidance from Royal College of Obstetricians and Gynaecologists require alternative strategies. TPMT deficiency and NUDT15 variants identified in genetic studies at Kyoto University and University of California, San Diego increase risk of severe myelosuppression, prompting genotype or phenotype screening recommended by Clinical Pharmacogenetics Implementation Consortium and national agencies. Live vaccines are generally contraindicated during significant immunosuppression according to CDC and Public Health England guidance.

Interactions

Interactions with xanthine oxidase inhibitors such as allopurinol and febuxostat—studied at Mayo Clinic and Massachusetts General Hospital—increase active metabolite levels and risk of toxicity, requiring dose adjustments described in prescribing information filed with the Food and Drug Administration and European Medicines Agency. Concomitant use with cytotoxic chemotherapy agents, biologics like anti-TNF agents evaluated in trials at University of Pennsylvania and Karolinska Institutet, or other immunosuppressants such as ciclosporin and tacrolimus used in transplant regimens at Cleveland Clinic alters infection and malignancy risk profiles discussed in transplant society guidelines. Drug interaction surveillance by Institute for Safe Medication Practices and pharmacovigilance programs at national medicines agencies informs risk mitigation.

History and society

Azathioprine was developed in the 1950s with seminal contributions from researchers at University of Leeds, Wellcome Trust, Oxford University, and pharmaceutical laboratories connected to GlaxoSmithKline predecessors; early clinical adoption in transplantation was led by teams at Peter Bent Brigham Hospital and Toronto General Hospital. Major trials and consensus statements from organizations such as the International Society for Heart and Lung Transplantation, American Society of Transplantation, and European Society of Organ Transplantation shaped its role in immunosuppression. Accessibility and cost issues have been addressed by health technology assessments from National Institute for Health and Care Excellence and reimbursement decisions by national health services in Canada, United Kingdom, and Australia. Ongoing research programs at institutions including NIH, Wellcome Trust Sanger Institute, European Molecular Biology Laboratory, and major universities continue to refine genetic testing, comparative effectiveness, and long-term safety monitoring.

Category:Immunosuppressive agents